- Home
- NBBK vs PHAR Comparison
NBBK vs PHAR Comparison
Compare NBBK & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBBK | PHAR |
|---|---|---|
| Founded | 1892 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.0M | 1.1B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NBBK | PHAR |
|---|---|---|
| Price | $22.25 | $17.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $23.50 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 190.7K | 16.3K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | ★ 25.23 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $45.15 | $10.04 |
| Revenue Next Year | $4.18 | $2.51 |
| P/E Ratio | ★ $16.71 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.44 | $8.02 |
| 52 Week High | $22.75 | $21.34 |
Technical Indicators
Market Signals| Indicator | NBBK | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 59.72 |
| Support Level | $20.17 | $17.25 |
| Resistance Level | $22.65 | $17.60 |
| Average True Range (ATR) | 0.44 | 0.61 |
| MACD | 0.19 | 0.16 |
| Stochastic Oscillator | 80.72 | 85.57 |
Price Performance
Historical ComparisonAbout NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.